Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from RELIEF THERAPEUTICS Holding ( (CH:RLF) ) is now available.
Relief Therapeutics announced positive results from a pivotal bioequivalence study of RLF-OD032, a liquid formulation of sapropterin dihydrochloride for treating phenylketonuria (PKU). The study confirmed that RLF-OD032 is bioequivalent to KUVAN® Powder, supporting a planned NDA submission in early 2026. This innovation offers a patient-friendly alternative by significantly reducing the volume of medication required, potentially improving adherence and quality of life for PKU patients. If approved, RLF-OD032 would be the first ready-to-use liquid sapropterin formulation, with patent protection extending through at least 2043.
The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF3.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company focused on developing innovative treatments for rare and debilitating diseases. The company specializes in drug delivery systems and drug repurposing, with a clinical pipeline targeting unmet medical needs in dermatological, metabolic, and respiratory conditions. Based in Geneva, Relief has successfully brought several products to market through licensing and distribution partnerships.
Average Trading Volume: 43,597
Technical Sentiment Signal: Buy
Current Market Cap: CHF35.49M
See more data about RLF stock on TipRanks’ Stock Analysis page.